灌注引导下的血管内超选择性动脉内灌注治疗恶性脑肿瘤。
Perfusion-guided endovascular super-selective intra-arterial infusion for treatment of malignant brain tumors.
作者信息
Chen Stephen R, Chen Melissa M, Ene Chibawanye, Lang Frederick F, Kan Peter
机构信息
Interventional Radiology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Diagnostic Radiology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
出版信息
J Neurointerv Surg. 2022 Jun;14(6):533-538. doi: 10.1136/neurintsurg-2021-018190. Epub 2021 Nov 25.
BACKGROUND
Survival for glioblastoma remains very poor despite decades of research, with a 5-year survival of only 5%. The technological improvements that have revolutionized treatment of ischemic stroke and brain aneurysms have great potential in providing more precise and selective delivery of cancer therapeutic agents to brain tumors.
METHODS
We describe for the first time the use of perfusion guidance to enhance the precision of endovascular super-selective intra-arterial (ESIA) infusions of mesenchymal stem cells loaded with Delta-24 (MSC-D24) in the treatment of glioblastoma (NCT03896568).
RESULTS
MRI imaging, which best defines the location of the tumor, is co-registered and fused with the patient's position using cone beam CT, resulting in optimal vessel selection and confirmation of targeted delivery through volumetric perfusion imaging.
CONCLUSIONS
This technique of perfusion guided-ESIA injections (PG-ESIA) enhances our ability to perform targeted super-selective delivery of therapeutic agents for brain tumors.
背景
尽管经过数十年研究，胶质母细胞瘤患者的生存率仍然很低，5年生存率仅为5%。在缺血性中风和脑动脉瘤治疗方面带来变革的技术进步，在为脑肿瘤更精确、更有选择性地输送癌症治疗药物方面具有巨大潜力。
方法
我们首次描述了使用灌注引导来提高血管内超选择性动脉内（ESIA）输注负载Delta-24的间充质干细胞（MSC-D24）治疗胶质母细胞瘤的精度（NCT03896568）。
结果
最能明确肿瘤位置的MRI成像与患者位置通过锥形束CT进行配准和融合，从而实现最佳血管选择，并通过容积灌注成像确认靶向递送。
结论
这种灌注引导的ESIA注射技术（PG-ESIA）提高了我们为脑肿瘤进行靶向超选择性治疗药物递送的能力。
Zotero 插件